

# Financial Tear Sheet

## Primary IR Contact

Ed Bell  
T +1 206-272-4345  
invest@ctibiopharma.com  
(mailto:invest@ctibiopharma.com)

## Transfer Agent

### Computershare

Mail:  
Computershare Investor Services  
P.O. Box 43078  
Providence, RI 02940-3078

Overnight Delivery:  
Computershare Investor Services  
250 Royall Street  
Canton, MA 02021  
United States of America

T: 312-588-4187  
F: 312-601-4332  
www.Computershare.com  
(http://www.computershare.com)

## Corporate Profile

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma's lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited.

## Stock Performance: CTIC (Nasdaq)

Exchange NASDAQ CM (US Dollar)

Price **\$1.27**

Change  
(%) ▼ 0.02 (1.55%)

Volume 221,940

52 Week Low \$0.60

Market Cap \$74,805,245

Rolling EPS -0.86

PE Ratio 0

Shares Outstanding 57,988,562

Data as of 01/15/19 4:00 p.m. ET



## Recent Headlines & Events

Dec 28, 2018 - 7:00 a.m.

CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib ([phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2381686](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2381686))

Dec 18, 2018 - 4:01 p.m.

CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development ([phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2381086](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2381086))

Dec 13, 2018 - 10:03 a.m.

CTI BioPharma Announces Restructuring Plan ([phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2380601](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2380601))

There are currently no events scheduled.

## Ownership Summary

### Shareholders

	<b>Holders</b>	<b>Value (\$MM)</b>	<b>% O/S</b>	<b>Shares</b>
Institution	111	79.15	62.8	36,418,184
Mutual Fund	107	8.41	10.2	5,895,938
Insider *	4	.48	0.3	168,978

*\*Insider values reflect direct beneficial ownership.*

### Top Holders

	<b>Shares Held</b>	<b>% O/S</b>	<b>Share Change</b>	<b>Filing Date</b>
BVF Partners L.P.	6,929,690	12.0	0	09/30/18
Stonepine Capital Management, LLC	5,302,063	9.1	1,252,765	09/30/18
OrbiMed Advisors, LLC	5,000,000	8.6	0	09/30/18
New Enterprise Associates (NEA)	3,750,000	6.5	0	09/30/18
BlackRock Institutional Trust Company, N.A.	2,632,579	4.5	68,540	09/30/18
The Vanguard Group, Inc.	2,387,830	4.1	-1,021	09/30/18
Opaleye Management Inc.	1,550,000	2.7	1,388,600	09/30/18
Fidelity Management & Research Company	949,700	1.6	-450,300	09/30/18
State Street Global Advisors (US)	856,518	1.5	21,040	09/30/18
Renaissance Technologies LLC	761,561	1.3	-11,884	09/30/18

*Data provided by Nasdaq. Minimum 15 minutes delayed.*